Vadimezan (BioDeep_00000178489)

   

human metabolite blood metabolite


代谢物信息卡片


2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid

化学式: C17H14O4 (282.0892044)
中文名称: 2,5-己酮可可碱
谱图信息: 最多检出来源 Homo sapiens(blood) 1.56%

分子结构信息

SMILES: CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2
InChI: InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)

描述信息

C26170 - Protective Agent > C275 - Antioxidant > C306 - Bioflavonoid
D000970 - Antineoplastic Agents

同义名列表

23 个代谢物同义名

2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid; 5,6-Dimethylxanthenoneacetic acid, sodium salt; 2-(5,6-Dimethyl-9-oxo-9H-xanthen-4-yl)acetate; 5,6-Dimethyl-9-oxo-9H-xanthene-4-acetic acid; (5,6-Dimethyl-9-oxoxanthen-4-yl)acetic acid; 5,6-Dimethyl-9-oxo-9H-xanthene-4-acetate; (5,6-Dimethyl-9-oxoxanthen-4-yl)acetate; 5,6-Dimethylxanthenone-4-acetic acid; 5,6-Dimethyl xanthenone acetic acid; 5,6-Dimethylxanthenoneacetic acid; 5,6-Dimethylxanthenone-4-acetate; Dimethyloxoxanthene acetic acid; 5,6-Dimethylxanthenoneacetate; Dimethyloxoxanthene acetate; DMXAA (Vadimezan); Vadimezanum; NSC 640488; 5,6-MeXAA; Vadimezan; AS 1404; ASA 404; AS-1404; ASA-404



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yeping Yu, Ling Chang, Qingluan Hu, Jianjun Zhu, Jianjun Zhang, Qiang Xia, Jie Zhao. P2rx1 deficiency alleviates acetaminophen-induced acute liver failure by regulating the STING signaling pathway. Cell biology and toxicology. 2023 Apr; ?(?):. doi: 10.1007/s10565-023-09800-1. [PMID: 37046119]
  • Jincai Wen, Shuanglin Qin, Yurong Li, Ping Zhang, Xiaoyan Zhan, Mingxia Fang, Ce Shi, Wenqing Mu, Wen Kan, Jia Zhao, Siwen Hui, Manting Hou, Hui Li, Xiaohe Xiao, Guang Xu, Zhaofang Bai. Flavonoids derived from licorice suppress LPS-induced acute lung injury in mice by inhibiting the cGAS-STING signaling pathway. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2023 Mar; 175(?):113732. doi: 10.1016/j.fct.2023.113732. [PMID: 36958387]
  • Qiongyuan Hu, Huajian Ren, Guanwei Li, Dingyu Wang, Quan Zhou, Jie Wu, Jiashuo Zheng, Jinjian Huang, Dominic A Slade, Xiuwen Wu, Jianan Ren. STING-mediated intestinal barrier dysfunction contributes to lethal sepsis. EBioMedicine. 2019 Mar; 41(?):497-508. doi: 10.1016/j.ebiom.2019.02.055. [PMID: 30878597]
  • Yongsheng Yu, Yu Liu, Weishuai An, Jingwen Song, Yuefan Zhang, Xianxian Zhao. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. The Journal of clinical investigation. 2019 02; 129(2):546-555. doi: 10.1172/jci121842. [PMID: 30561388]
  • Xuan Yi, Meiyun Xu, Hailin Zhou, Saisai Xiong, Rui Qian, Zhifang Chai, Li Zhao, Kai Yang. Ultrasmall Hyperbranched Semiconducting Polymer Nanoparticles with Different Radioisotopes Labeling for Cancer Theranostics. ACS nano. 2018 09; 12(9):9142-9151. doi: 10.1021/acsnano.8b03514. [PMID: 30180555]
  • Jie Liu, Cao Zhang, Huailing Wang, Lei Zhang, Zhenlei Jiang, Jianrun Zhang, Zhijun Liu, Heru Chen. Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity. European journal of medicinal chemistry. 2018 May; 151(?):158-172. doi: 10.1016/j.ejmech.2018.03.072. [PMID: 29609121]
  • Jie Liu, Fan Zhou, Lei Zhang, Huailing Wang, Jianrun Zhang, Cao Zhang, Zhenlei Jiang, Yanbing Li, Zhijun Liu, Heru Chen. DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions. European journal of medicinal chemistry. 2018 Jan; 143(?):1768-1778. doi: 10.1016/j.ejmech.2017.10.074. [PMID: 29129511]
  • Xin Guo, Chang Shu, Honggui Li, Ya Pei, Shih-Lung Woo, Juan Zheng, Mengyang Liu, Hang Xu, Rachel Botchlett, Ting Guo, Yuli Cai, Xinsheng Gao, Jing Zhou, Lu Chen, Qifu Li, Xiaoqiu Xiao, Linglin Xie, Ke K Zhang, Jun-Yuan Ji, Yuqing Huo, Fanyin Meng, Gianfranco Alpini, Pingwei Li, Chaodong Wu. Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation and Regulates Proinflammatory Responses Distinctly from STING Activation. Scientific reports. 2017 07; 7(1):6355. doi: 10.1038/s41598-017-05884-y. [PMID: 28743914]
  • Jie Liu, Jianrun Zhang, Huailing Wang, Zhijun Liu, Cao Zhang, Zhenlei Jiang, Heru Chen. Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them. European journal of medicinal chemistry. 2017 Jun; 133(?):50-61. doi: 10.1016/j.ejmech.2017.03.068. [PMID: 28376372]
  • Xing Che, Xiao-Xia Du, Xiaoxia Cai, Jun Zhang, Wen Jun Xie, Zhuoran Long, Zhao-Yang Ye, Heng Zhang, Lijiang Yang, Xiao-Dong Su, Yi Qin Gao. Single Mutations Reshape the Structural Correlation Network of the DMXAA-Human STING Complex. The journal of physical chemistry. B. 2017 03; 121(9):2073-2082. doi: 10.1021/acs.jpcb.6b12472. [PMID: 28178416]
  • Kojiro Mukai, Hiroyasu Konno, Tatsuya Akiba, Takefumi Uemura, Satoshi Waguri, Toshihide Kobayashi, Glen N Barber, Hiroyuki Arai, Tomohiko Taguchi. Activation of STING requires palmitoylation at the Golgi. Nature communications. 2016 06; 7(?):11932. doi: 10.1038/ncomms11932. [PMID: 27324217]
  • Heng Zhang, Min-Jie Han, Jianli Tao, Zhao-Yang Ye, Xiao-Xia Du, Ming-Jing Deng, Xiao-Yan Zhang, Lan-Fen Li, Zheng-Fan Jiang, Xiao-Dong Su. Rat and human STINGs profile similarly towards anticancer/antiviral compounds. Scientific reports. 2015 Dec; 5(?):18035. doi: 10.1038/srep18035. [PMID: 26669264]
  • Hong Li, Ganggang Li, Linxin Liu, Zhenzhen Guo, Xiaofang Ma, Ning Cao, Haihong Lin, Guang Han, Yongjian Duan, Gangjun Du. Tumor interstitial fluid promotes malignant phenotypes of lung cancer independently of angiogenesis. Cancer prevention research (Philadelphia, Pa.). 2015 Nov; 8(11):1120-9. doi: 10.1158/1940-6207.capr-15-0242. [PMID: 26342025]
  • Afnan Batubara, Vikki A Carolan, Paul M Loadman, Chris Sutton, Steve D Shnyder, Malcolm R Clench. Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA. Rapid communications in mass spectrometry : RCM. 2015 Jul; 29(14):1288-96. doi: 10.1002/rcm.7223. [PMID: 26405790]
  • Raymond Yung, Vahid Seyfoddin, Christopher Guise, Sofian Tijono, Ailsa McGregor, Bronwen Connor, Lai-Ming Ching. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Cancer chemotherapy and pharmacology. 2014 Mar; 73(3):639-49. doi: 10.1007/s00280-014-2395-y. [PMID: 24477604]
  • M J McKeage, P C Fong, X Hong, J Flarakos, J Mangold, Y Du, C Tanaka, H Schran. Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial. Cancer chemotherapy and pharmacology. 2012 May; 69(5):1145-54. doi: 10.1007/s00280-011-1809-3. [PMID: 22212299]
  • Leigh Ellis, Preeti Shah, Hans Hammers, Kristin Lehet, Paula Sotomayor, Gissou Azabdaftari, Mukund Seshadri, Roberto Pili. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular cancer therapeutics. 2012 Feb; 11(2):383-92. doi: 10.1158/1535-7163.mct-11-0748. [PMID: 22084164]
  • Wenkui Li, Hui Lin, Harold T Smith, Francis L S Tse. Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2011 Jul; 879(21):1927-33. doi: 10.1016/j.jchromb.2011.05.012. [PMID: 21680264]
  • Ena Wang, Scott Bussom, Jinguo Chen, Courtney Quinn, Davide Bedognetti, Wing Lam, Fulan Guan, Zaoli Jiang, Yichao Mark, Yingdong Zhao, David F Stroncek, Jeffrey White, Francesco M Marincola, Yung-Chi Cheng. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC medical genomics. 2011 May; 4(?):38. doi: 10.1186/1755-8794-4-38. [PMID: 21569348]
  • Toyoaki Hida, Motohiro Tamiya, Makoto Nishio, Nobuyuki Yamamoto, Tomonori Hirashima, Takeshi Horai, Hiromi Tanii, Michael M Shi, Ken Kobayashi, Yoshitsugu Horio. Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer science. 2011 Apr; 102(4):845-51. doi: 10.1111/j.1349-7006.2010.01839.x. [PMID: 21205086]
  • J D Lickliter, A B Francesconi, G Smith, M Burge, A Coulthard, S Rose, M Griffin, R Milne, J McCarron, T Yeadon, A Wilks, A Cubitt, D K Wyld, P A Vasey. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British journal of cancer. 2010 Aug; 103(5):597-606. doi: 10.1038/sj.bjc.6605841. [PMID: 20733579]
  • Guanjun Cheng, Jing Sun, Zvi G Fridlender, Liang-Chuan S Wang, Lai-Ming Ching, Steven M Albelda. Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan). The Journal of biological chemistry. 2010 Apr; 285(14):10553-62. doi: 10.1074/jbc.m109.065631. [PMID: 20118240]
  • Liang-Chuan S Wang, Lotte Thomsen, Rachel Sutherland, Charu B Reddy, Sofian M Tijono, Chun-Jen J Chen, Catherine E Angel, P Rod Dunbar, Lai-Ming Ching. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia (New York, N.Y.). 2009 Aug; 11(8):793-803. doi: 10.1593/neo.09506. [PMID: 19649209]
  • M J McKeage, J Von Pawel, M Reck, M B Jameson, M A Rosenthal, R Sullivan, D Gibbs, P N Mainwaring, M Serke, J-J Lafitte, C Chouaid, L Freitag, E Quoix. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British journal of cancer. 2008 Dec; 99(12):2006-12. doi: 10.1038/sj.bjc.6604808. [PMID: 19078952]
  • Marie Van de Putte, Yicheng Ni, Peter A M De Witte. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncology reports. 2008 Apr; 19(4):921-6. doi: NULL. [PMID: 18357376]
  • Jing Li, Michael B Jameson, Bruce C Baguley, Roberto Pili, Sharyn D Baker. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Apr; 14(7):2102-10. doi: 10.1158/1078-0432.ccr-07-1475. [PMID: 18381951]
  • Francisco Chung, Jenny Liu, Lai-Ming Ching, Bruce C Baguley. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer chemotherapy and pharmacology. 2008 Mar; 61(3):497-502. doi: 10.1007/s00280-007-0495-7. [PMID: 17473922]
  • M Borel, F Degoul, Y Communal, E Mounetou, B Bouchon, R C-Gaudreault, J C Madelmont, E Miot-Noirault. N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice. British journal of cancer. 2007 Jun; 96(11):1684-91. doi: 10.1038/sj.bjc.6603778. [PMID: 17486131]
  • Xiaosong Zhang, Ming Zhao, Michelle A Rudek, Ping He, Bert Vogelstein. Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Jun; 852(1-2):217-22. doi: 10.1016/j.jchromb.2007.01.018. [PMID: 17307035]
  • M B Jameson, B C Baguley, P Kestell, L Zhao, J W Paxton, P I Thompson, S Waller. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer chemotherapy and pharmacology. 2007 Apr; 59(5):681-7. doi: 10.1007/s00280-006-0322-6. [PMID: 17021822]
  • Mark J McKeage, Peter Fong, Mark Jeffery, Bruce C Baguley, Phil Kestell, Miroslav Ravic, Michael B Jameson. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Mar; 12(6):1776-84. doi: 10.1158/1078-0432.ccr-05-1939. [PMID: 16551862]
  • Lesley D McPhail, Dominick J O McIntyre, Christian Ludwig, Philip Kestell, John R Griffiths, Lloyd R Kelland, Simon P Robinson. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia (New York, N.Y.). 2006 Mar; 8(3):199-206. doi: 10.1593/neo.05739. [PMID: 16611413]
  • Peter Kovacic. Fundamental, electron transfer mechanism by pyrylium-type ions for the anticancer drugs 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA). Current medicinal chemistry. Anti-cancer agents. 2005 Sep; 5(5):501-6. doi: 10.2174/1568011054866919. [PMID: 16178775]
  • Liangli Zhao, Lai-Ming Ching, Philip Kestell, Lloyd R Kelland, Bruce C Baguley. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. International journal of cancer. 2005 Aug; 116(2):322-6. doi: 10.1002/ijc.21005. [PMID: 15800918]
  • Francisco Chung, Liang-Chuan S Wang, Philip Kestell, Bruce C Baguley, Lai-Ming Ching. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer chemotherapy and pharmacology. 2004 May; 53(5):377-83. doi: 10.1007/s00280-003-0753-2. [PMID: 15060740]
  • Philip E Thorpe. Vascular targeting agents as cancer therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Jan; 10(2):415-27. doi: 10.1158/1078-0432.ccr-0642-03. [PMID: 14760060]
  • Liangli Zhao, Lai-Ming Ching, Philip Kestell, Bruce C Baguley. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Dec; 9(17):6545-50. doi: NULL. [PMID: 14695159]
  • Shufeng Zhou, Philip Kestell, Bruce C Baguley, James W Paxton. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical pharmacology. 2003 Jun; 65(11):1853-65. doi: 10.1016/s0006-2952(03)00189-8. [PMID: 12781337]
  • Bronwyn G Siim, Alan E Lee, Sahar Shalal-Zwain, Frederik B Pruijn, Mark J McKeage, William R Wilson. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer chemotherapy and pharmacology. 2003 Jan; 51(1):43-52. doi: 10.1007/s00280-002-0529-0. [PMID: 12497205]
  • Francisco Chung, Brian D Palmer, George W Muller, Hon-Wah Man, Phillip Kestell, Bruce C Baguley, Lai-Ming Ching. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncology research. 2003; 14(2):75-82. doi: 10.3727/000000003108748621. [PMID: 14649541]
  • Bruce C Baguley, Lai Ming Ching. DMXAA: an antivascular agent with multiple host responses. International journal of radiation oncology, biology, physics. 2002 Dec; 54(5):1503-11. doi: 10.1016/s0360-3016(02)03920-2. [PMID: 12459378]
  • Shufeng Zhou, Philip Kestell, James W Paxton. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug metabolism reviews. 2002 Nov; 34(4):751-90. doi: 10.1081/dmr-120015693. [PMID: 12487149]
  • L Zhao, L-M Ching, P Kestell, B C Baguley. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. British journal of cancer. 2002 Aug; 87(4):465-70. doi: 10.1038/sj.bjc.6600479. [PMID: 12177785]
  • Shufeng Zhou, Philip Kestell, Bruce C Baguley, James W Paxton. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Investigational new drugs. 2002 Aug; 20(3):281-95. doi: 10.1023/a:1016215015530. [PMID: 12201491]
  • K Hori, S Saito, K Kubota. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. British journal of cancer. 2002 May; 86(10):1604-14. doi: 10.1038/sj.bjc.6600296. [PMID: 12085211]
  • S F Zhou, M D Tingle, P Kestell, J W Paxton. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica; the fate of foreign compounds in biological systems. 2002 Feb; 32(2):87-107. doi: 10.1080/00498250110092423. [PMID: 11868972]
  • Shufeng Zhou, Philip Kestell, Malcolm D Tingle, James W Paxton. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer chemotherapy and pharmacology. 2002 Feb; 49(2):126-32. doi: 10.1007/s00280-001-0383-5. [PMID: 11862426]
  • Liangli Zhao, Philip Kestell, Lai-Ming Ching, Bruce C Baguley. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer chemotherapy and pharmacology. 2002 Jan; 49(1):20-6. doi: 10.1007/s00280-001-0377-3. [PMID: 11855749]
  • Shufeng Zhou, Philip Kestell, Malcolm D Tingle, James W Paxton. Thalidomide in cancer treatment: a potential role in the elderly?. Drugs & aging. 2002; 19(2):85-100. doi: 10.2165/00002512-200219020-00002. [PMID: 11950376]
  • P Kestell, L Zhao, M B Jameson, M R Stratford, L K Folkes, B C Baguley. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clinica chimica acta; international journal of clinical chemistry. 2001 Dec; 314(1-2):159-66. doi: 10.1016/s0009-8981(01)00692-1. [PMID: 11718691]
  • S Zhou, R Chin, P Kestell, M D Tingle, J W Paxton. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. British journal of clinical pharmacology. 2001 Aug; 52(2):129-36. doi: 10.1046/j.0306-5251.2001.01438.x. [PMID: 11488768]
  • S Zhou, J W Paxton, M D Tingle, P Kestell. Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 2001 Jun; 757(2):343-8. doi: 10.1016/s0378-4347(01)00173-6. [PMID: 11417880]
  • S Zhou, J W Paxton, M D Tingle, P Kestell. Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. Journal of chromatography. B, Biomedical sciences and applications. 2001 Jun; 757(2):359-63. doi: 10.1016/s0378-4347(01)00177-3. [PMID: 11417882]
  • L Zhao, P Kestell, M Philpott, L M Ching, L Zhuang, B C Baguley. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer chemotherapy and pharmacology. 2001 Jun; 47(6):491-7. doi: 10.1007/s002800000267. [PMID: 11459201]
  • S Zhou, P Kestell, M D Tingle, L M Ching, J W Paxton. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. Cancer chemotherapy and pharmacology. 2001 Jun; 47(6):541-4. doi: 10.1007/s002800100285. [PMID: 11459209]
  • S F Zhou, J W Paxton, M D Tingle, P Kestell, M B Jameson, P I Thompson, B C Baguley. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica; the fate of foreign compounds in biological systems. 2001 May; 31(5):277-93. doi: 10.1080/00498250110043544. [PMID: 11491389]
  • S Zhou, J W Paxton, P Kestell, M D Tingle. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. The Journal of pharmacy and pharmacology. 2001 Apr; 53(4):463-71. doi: 10.1211/0022357011775758. [PMID: 11341362]
  • S Zhou, J W Paxton, P Kestell, M D Tingle, L M Ching. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer chemotherapy and pharmacology. 2001 Apr; 47(4):319-26. doi: 10.1007/s002800000249. [PMID: 11345648]
  • R Murata, J Overgaard, M R Horsman. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. International journal of radiation biology. 2001 Feb; 77(2):195-204. doi: 10.1080/09553000010007695. [PMID: 11236926]
  • P Kestell, L Zhao, B C Baguley, B D Palmer, G Muller, J W Paxton, L M Ching. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer chemotherapy and pharmacology. 2000; 46(2):135-41. doi: 10.1007/s002800000131. [PMID: 10972483]
  • Z Cao, W R Joseph, W L Browne, K G Mountjoy, B D Palmer, B C Baguley, L M Ching. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. British journal of cancer. 1999 May; 80(5-6):716-23. doi: 10.1038/sj.bjc.6690415. [PMID: 10360649]
  • W R Joseph, Z Cao, K G Mountjoy, E S Marshall, B C Baguley, L M Ching. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer research. 1999 Feb; 59(3):633-8. doi: NULL. [PMID: 9973211]
  • P Kestell, J W Paxton, G W Rewcastle, I Dunlop, B C Baguley. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer chemotherapy and pharmacology. 1999; 43(4):323-30. doi: 10.1007/s002800050902. [PMID: 10071984]
  • W L Browne, W R Wilson, B C Baguley, L M Ching. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer research. 1998 Nov; 18(6A):4409-13. doi: NULL. [PMID: 9891501]
  • L M Ching, W L Browne, R Tchernegovski, T Gregory, B C Baguley, B D Palmer. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. British journal of cancer. 1998 Aug; 78(3):336-43. doi: 10.1038/bjc.1998.495. [PMID: 9703279]
  • J H Pang, Z Cao, W R Joseph, B C Baguley, L M Ching. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. European journal of cancer (Oxford, England : 1990). 1998 Jul; 34(8):1282-9. doi: 10.1016/s0959-8049(98)00050-1. [PMID: 9849492]
  • E Moilanen, L L Thomsen, D W Miles, D W Happerfield, R G Knowles, S Moncada. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. British journal of cancer. 1998; 77(3):426-33. doi: 10.1038/bjc.1998.68. [PMID: 9472639]
  • J O Miners, L Valente, K J Lillywhite, P I Mackenzie, B Burchell, B C Baguley, P Kestell. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer research. 1997 Jan; 57(2):284-9. doi: . [PMID: 9000569]
  • B C Baguley, L Zhuang, P Kestell. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncology research. 1997; 9(2):55-60. doi: NULL. [PMID: 9167186]
  • F B Pruijn, M van Daalen, N H Holford, W R Wilson. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer chemotherapy and pharmacology. 1997; 39(6):541-6. doi: 10.1007/s002800050611. [PMID: 9118467]
  • M E Watts, S Arnold, D J Chaplin. Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA. The British journal of cancer. Supplement. 1996 Jul; 27(?):S164-7. doi: NULL. [PMID: 8763872]
  • L M Ching, Z F Xu, B H Gummer, B D Palmer, W R Joseph, B C Baguley. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. British journal of cancer. 1995 Aug; 72(2):339-43. doi: 10.1038/bjc.1995.335. [PMID: 7640215]
  • L K Webster, A G Ellis, P Kestell, G W Rewcastle. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug metabolism and disposition: the biological fate of chemicals. 1995 Mar; 23(3):363-8. doi: NULL. [PMID: 7628302]
  • M Philpott, B C Baguley, L M Ching. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer chemotherapy and pharmacology. 1995; 36(2):143-8. doi: 10.1007/bf00689199. [PMID: 7767951]
  • S N Vogel, C L Manthey, P Y Perera, Z Y Li, B E Henricson. Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS. Progress in clinical and biological research. 1995; 392(?):421-31. doi: ". [PMID: 8524949]
  • L M Ching, W R Joseph, L Zhuang, B C Baguley. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer chemotherapy and pharmacology. 1994; 35(2):153-60. doi: 10.1007/bf00686639. [PMID: 7987993]
  • E Veszelovszky, L L Thomsen, Z Li, B C Baguley. Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis. European journal of cancer (Oxford, England : 1990). 1993; 29A(3):404-8. doi: 10.1016/0959-8049(93)90396-w. [PMID: 8398341]
  • B C Baguley, G Cole, L L Thomsen, Z Li. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer chemotherapy and pharmacology. 1993; 33(1):77-81. doi: 10.1007/bf00686027. [PMID: 8269593]
  • M J McKeage, P Kestell, W A Denny, B C Baguley. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer chemotherapy and pharmacology. 1991; 28(6):409-13. doi: 10.1007/bf00685815. [PMID: 1934244]